Suvratoxumab (INN;[1] development code MEDI4893) is a human monoclonal antibody designed for the prevention of nosocomial pneumonia caused by Staphylococcus aureus.

This drug was developed by MedImmune[2]

References

  1. ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Suvratoxumab, American Medical Association.
Allikas: https://en.wikipedia.org/wiki/Suvratoxumab
No tags for this post.